日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance

卵巢上皮癌中类固醇受体共激活因子3的表达是预后不良因素,也是铂类耐药性的标志物。

Palmieri, C; Gojis, O; Rudraraju, B; Stamp-Vincent, C; Wilson, D; Langdon, S; Gourley, C; Faratian, D

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

雌激素受体结合差异与乳腺癌临床结果相关

Caryn S Ross-Innes, Rory Stark, Andrew E Teschendorff, Kelly A Holmes, H Raza Ali, Mark J Dunning, Gordon D Brown, Ondrej Gojis, Ian O Ellis, Andrew R Green, Simak Ali, Suet-Feung Chin, Carlo Palmieri, Carlos Caldas, Jason S Carroll

NT5E CpG island methylation is a favourable breast cancer biomarker

NT5E CpG岛甲基化是一种有利的乳腺癌生物标志物

Lo Nigro, C; Monteverde, M; Lee, S; Lattanzio, L; Vivenza, D; Comino, A; Syed, N; McHugh, A; Wang, H; Proby, C; Garrone, O; Merlano, M; Hatzimichael, E; Briasoulis, E; Gojis, O; Palmieri, C; Jordan, L; Quinlan, P; Thompson, A; Crook, T

High frequency of complex TP53 mutations in CNS metastases from breast cancer

乳腺癌中枢神经系统转移灶中TP53复杂突变发生率高

Lo Nigro, C; Vivenza, D; Monteverde, M; Lattanzio, L; Gojis, O; Garrone, O; Comino, A; Merlano, M; Quinlan, P R; Syed, N; Purdie, C A; Thompson, A; Palmieri, C; Crook, T

FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer

FoxM1 是乳腺癌中 HER2 过表达的下游靶点和标志物

Richard E Francis, Stephen S Myatt, Janna Krol, Johan Hartman, Barrie Peck, Ursula B McGovern, Jun Wang, Stephanie K Guest, Aleksandra Filipovic, Ondrej Gojis, Carlo Palmieri, David Peston, Sami Shousha, Qunyan Yu, Piotr Sicinski, R Charles Coombes, Eric W-F Lam